<p>(a) Relative cell viability of LH86 (target cell line); (b) Relative cell viability of Hu1229 (human normal liver cells); (c) Hoechst 33258 staining for apoptotic and dead LH86 cells treated with a series of concentrations of TLS11a-GC-Dox or TD05-GC-Dox; (d) Western blot results for cleaved caspase 3 in LH86 cells treated with a series of concentrations of TLS11a-GC-Dox or TD05-GC-Dox.</p
<p>A) QRT-PCR for Drosha in HCT116 WT, and DROSHA shRNA cells, with or without 500 ng/ml of Doxycycl...
<p>(A) HeLa or KMS34 cells were treated with 0–50 µM TC11 or thalidomide for 24 h. The whole cell ly...
<p>(A) The cells of GS102, GS224 and GS289 cells were concomitantly treated with HDACi and Delta24-R...
<p>(A) Cytotoxic activity of compounds <b>1</b>, <b>2</b>, and <b>5</b> against cancer cells. The in...
<p><b>(A)</b> Cell viability under Dox-treatment. CSCs were treated with Dox for 48hrs at the indica...
Percent viable and apoptotic cells for DU145, DU145-TXR after DTX time course treatment.</p
<p>(A) Pre-treatment with L-165141decreases the number of doxorubicin-induced apoptotic cells. Bcl6 ...
<p>A panel of cancer cell lines (black color) and a normal liver hepatocyte cell line (red color) we...
<p><b>A</b>. Caspase 3/7 activity of HT1080 and HCT116 cells treated with increasing concentrations ...
Multidrug Resistance is a major obstacle in cancer chemotherapy. The current study was designed to e...
<p>QBC939 and HepG2 cells were treated with cisplatin for 12 or 24 h, and then cell viability, apopt...
<p>(A) Cell viability was assessed by XTT colorimetric assay performed at 24 h and 7 days post Plasm...
<p>(<b>A</b>) MTT-Assay of SW480 and HT29 cells after knockdown of Mcl-1, Bcl-2 and Bcl-x<sub>L</sub...
<p>Cells were treated with 10 µM or 20 µM each of CY2, CY14, CY15 for 24 h or left as such. Cells we...
<p><b>A</b> SH-SY5Y NB cells were treated as indicated by the scheme and apoptosis was determined by...
<p>A) QRT-PCR for Drosha in HCT116 WT, and DROSHA shRNA cells, with or without 500 ng/ml of Doxycycl...
<p>(A) HeLa or KMS34 cells were treated with 0–50 µM TC11 or thalidomide for 24 h. The whole cell ly...
<p>(A) The cells of GS102, GS224 and GS289 cells were concomitantly treated with HDACi and Delta24-R...
<p>(A) Cytotoxic activity of compounds <b>1</b>, <b>2</b>, and <b>5</b> against cancer cells. The in...
<p><b>(A)</b> Cell viability under Dox-treatment. CSCs were treated with Dox for 48hrs at the indica...
Percent viable and apoptotic cells for DU145, DU145-TXR after DTX time course treatment.</p
<p>(A) Pre-treatment with L-165141decreases the number of doxorubicin-induced apoptotic cells. Bcl6 ...
<p>A panel of cancer cell lines (black color) and a normal liver hepatocyte cell line (red color) we...
<p><b>A</b>. Caspase 3/7 activity of HT1080 and HCT116 cells treated with increasing concentrations ...
Multidrug Resistance is a major obstacle in cancer chemotherapy. The current study was designed to e...
<p>QBC939 and HepG2 cells were treated with cisplatin for 12 or 24 h, and then cell viability, apopt...
<p>(A) Cell viability was assessed by XTT colorimetric assay performed at 24 h and 7 days post Plasm...
<p>(<b>A</b>) MTT-Assay of SW480 and HT29 cells after knockdown of Mcl-1, Bcl-2 and Bcl-x<sub>L</sub...
<p>Cells were treated with 10 µM or 20 µM each of CY2, CY14, CY15 for 24 h or left as such. Cells we...
<p><b>A</b> SH-SY5Y NB cells were treated as indicated by the scheme and apoptosis was determined by...
<p>A) QRT-PCR for Drosha in HCT116 WT, and DROSHA shRNA cells, with or without 500 ng/ml of Doxycycl...
<p>(A) HeLa or KMS34 cells were treated with 0–50 µM TC11 or thalidomide for 24 h. The whole cell ly...
<p>(A) The cells of GS102, GS224 and GS289 cells were concomitantly treated with HDACi and Delta24-R...